Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.47 |
| ▸ | ITGAV | P06756 | 9/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492757 | 0.87 | ITGB3 (0.48) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL6493323 | 0.87 | ITGB3 (0.48) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7451827 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7451824 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7450546 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL6494656 | 0.82 | ITGB3 (0.44) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL6502448 | 0.81 | ABCB1 (0.35) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL6494185 | 0.81 | ITGB3 (0.41) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7452852 | 0.80 | ITGB3 (0.57) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7448314 | 0.80 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960594-B2 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | SHIRE BIOCHEM INC. (CA) | 2005-11-01 | — | — | US | disclosed |
| EP-1091952-B1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | IAF BIOCHEM INT (CA) | 2003-10-29 | — | — | EP | disclosed |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | BIOCHEM PHARMA INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1091952-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000486-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | ITGB5, ITGB2, ITGA2 | ITGB3 12/4885ITGA2B 10/4885ITGAV 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.